Paul Benanos
Director of Biopharma Intelligence with expertise in biopharma dealmaking and cell therapy commercialization, providing analysis of Gilead's acquisition of Arcellx.
Best podcasts with Paul Benanos
Ranked by the Snipd community
18 snips
Feb 24, 2026 • 35min
Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint
Steve Usdin, Washington editor covering policy and FDA moves. Lauren Martz, oncology biomarker and cell therapy development expert. Paul Benanos, dealmaking and cell therapy commercialization analyst. They discuss Gilead’s $7.8B acquisition of Arcellx and its implications. They explore ctDNA as a potential surrogate endpoint and the validation, standardization and trial hurdles that remain.
